Dalton Pharma Services and The Henry M. Jackson Foundation Announce a Services Agreement for the Advancement of Military Medicine
Dalton will scale up the conjugation and purification process of a capsule-protein conjugate vaccine intended for use in Phase 1 human clinical trials conducted by NMRC.
“Our expertise and capabilities in conjugation chemistry, sterile API manufacturing and our strength in aseptic filling, solidified the manufacturing agreement," said Peter Pekos, President and CEO of Dalton. “Dalton is committed to supporting the efforts of the Navy and the University of Guelph for novel vaccine research and development.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.